$78.630
-0.464 (-0.59%)收盤時
USPH 資訊
USPH 事件
USPH Reports Q2 Revenue of $214.1M, Beating Expectations
Reports Q2 revenue $214.1M, consensus $211.36M. Chris Reading, Chairman and Chief Executive Officer commented, "Our second quarter 2026 results include an important milestone for USPH as we completed the integration of 31 existing clinics into our hospital affiliations. The remaining 39 hospital affiliated clinics are expected to integrate in the third quarter, resulting in increasing physical therapy revenues and margins. Combined with the partial virtualization of front desk processes and expansion of cash-based programs in our largest partnerships, we expect to accelerate our year over year adjusted EBITDA improvement in the back half of 2026, and for these initiatives to propel us into 2027."
U.S. Physical Therapy Confirms FY26 Adjusted EBITDA Outlook of $102M-$106M
U.S. Physical Therapy backs FY26 adjusted EBITDA view $102M-$106M
U.S. Physical Therapy Acquires 12-Clinic Practice, Holds 67% Stake
U.S. Physical Therapy announced the acquisition of a twelve-clinic physical therapy practice, effective July 1, 2026. USPH acquired a 67% equity interest, with 33% retained by the current owners. The practice currently generates approximately 112,000 annual visits and $12 million in annual revenue. Graham Reeve, Chief Operating Officer-West, said, "We are thrilled to welcome our newest partners and our newest state to the USPH family. The expansion to a new state represents an important step in USPH's continuing growth. Our new partners are known for delivering exceptional clinical care while building trusted relationships within the communities they serve, and we look forward to building on this strong foundation together."
USPH Reaffirms 2026 EBITDA Guidance of $102M to $106M
Management reaffirmed the Company's full year 2026 adjusted EBITDA guidance of $102.0 million to $106.0 million, which includes the partial year impact of two previously announced hospital affiliations and the January 1, 2026 Medicare rate increase. The two previously announced strategic hospital alliances are expected to be accretive to the Company's revenue, EBITDA, and margins. Upon full integration of the 60 Metro clinics, the incremental annualized EBITDA contribution to Metro is expected to be at least $12 million, with the corresponding impact to USPH estimated to be at least $6 million, reflecting its 50% ownership interest in Metro. Upon full integration of the second subsidiary partner's ten clinics, the incremental annualized EBITDA contribution to the subsidiary partner is expected to be at least $2 million, with the corresponding impact to USPH estimated to be at least $1.3 million, reflecting its 65% ownership interest in the subsidiary partner. The Company's 2026 guidance reflects the phased ramp-up of these affiliations beginning May 2026.
Company Reports Q1 Revenue of $198.3M, Below Expectations
Reports Q1 revenue $198.3M, consensus $200.94M. Chris Reading, Chairman and Chief Executive Officer commented, "I want to begin by thanking our partners and clinical teams for their tremendous care and their continued efforts on behalf of our patients and across several important initiatives this year. These include a partial virtualization of our front desk; company-wide rollout of ambient-listening technology to improve documentation efficiency and allow for more patient-centric interaction; remote therapeutic monitoring for our traditional Medicare patients to facilitate greater home program adherence positively impacting care and outcomes; and targeted cash-based program expansion across our top partnerships impacting care and outcomes as well as overall margin. These initiatives, along with our very important hospital alliance focus, will bear fruit particularly in the second half of the year."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。